By Dean Seal

 

Nuvation Bio Inc. said Monday that the Food and Drug Administration has put a partial clinical hold on the Phase 1 dose escalation study of its drug candidate NUV-422.

The New York-based biopharmaceutical company said the trial aims to define the maximum tolerated dose for NUV-422 as a treatment for solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer.

The trial started enrolling patients 19 months ago, but following the emergence of a form of eye inflammation in certain patients, Nuvation paused enrollment and reached out to the FDA for guidance, the company said.

While the partial hold is in place, no new patients will be enrolled, though current participants may continue to be treated under the study, Nuvation said.

Share of Nuvation Bio fell 17% in premarket trading to $3.48.

 

Write to Dean Seal at dean.seal@wsj.com

 

(END) Dow Jones Newswires

June 27, 2022 08:00 ET (12:00 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Panacea Acquisition (NYSE:NUVB)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Panacea Acquisition Charts.
Panacea Acquisition (NYSE:NUVB)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Panacea Acquisition Charts.